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Aripiprazole increases the PKA signalling and expression of the GABAA receptor 
and CREB1 in the nucleus accumbens of rats 
Abstract 
The GABAA receptor is implicated in the pathophysiology of schizophrenia and regulated by PKA 
signalling. Current antipsychotics bind with D2-like receptors, but not the GABAA receptor. The cAMP-
responsive element-binding protein 1 (CREB1) is also associated with PKA signalling and may be related 
to the positive symptoms of schizophrenia. This study investigated the effects of antipsychotics in 
modulating D2-mediated PKA signalling and its downstream GABAA receptors and CREB1. Rats were 
treated orally with aripiprazole (0.75 mg/kg, ter in die (t.i.d.)), bifeprunox (0.8 mg/kg, t.i.d.), haloperidol 
(0.1 mg/kg, t.i.d.) or vehicle for 1 week. The levels of PKA-Cα and p-PKA in the prefrontal cortex (PFC), 
nucleus accumbens (NAc) and caudate putamen (CPu) were detected by Western blots. The mRNA levels 
of Gabrb1, Gabrb2, Gabrb3 and Creb1, and their protein expression were measured by qRT-PCR and 
Western blots, respectively. Aripiprazole elevated the levels of p-PKA and the ratio of p-PKA/PKA in the 
NAc, but not the PFC and CPu. Correlated with this elevated PKA signalling, aripiprazole elevated the 
mRNA and protein expression of the GABAA (β-1) receptor and CREB1 in the NAc. While haloperidol 
elevated the levels of p-PKA and the ratio of p-PKA/PKA in both NAc and CPu, it only tended to increase 
the expression of the GABAA (β-1) receptor and CREB1 in the NAc, but not the CPu. Bifeprunox had no 
effects on PKA signalling in these brain regions. These results suggest that aripiprazole has selective 
effects on upregulating the GABAA (β-1) receptor and CREB1 in the NAc, probably via activating PKA 
signalling. 
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The GABAA receptor is implicated in the pathophysiology of schizophrenia and regulated by 
PKA signalling. Current antipsychotics bind with D2-like receptors, but not the GABAA 
receptor. The cAMP-responsive element-binding protein 1 (CREB1) is also associated with 
PKA signalling and may be related to the positive symptoms of schizophrenia. This study 
investigated the effects of antipsychotics in modulating D2-mediated PKA signalling and its 
downstream GABAA receptors and CREB1. Rats were treated orally with aripiprazole 
(0.75mg/kg, t.i.d. (ter in die)), bifeprunox (0.8mg/kg, t.i.d.), haloperidol (0.1mg/kg, t.i.d.) or 
vehicle for 1 week. The levels of PKA-Cα and p-PKA in the prefrontal cortex (PFC), nucleus 
accumbens (NAc) and caudate putamen (CPu) were detected by Western Blots. The mRNA 
levels of Gabrb1, Gabrb2, Gabrb3 and Creb1, and their protein expression were measured by 
qRT-PCR and Western Blots, respectively. Aripiprazole elevated the levels of p-PKA and the 
ratio of p-PKA/PKA in the NAc, but not the PFC and CPu. Correlated with this elevated 
PKA signalling, aripiprazole elevated the mRNA and protein expression of the GABAA (β-1) 
receptor and CREB1 in the NAc. While haloperidol elevated the levels of p-PKA and the 
ratio of p-PKA/PKA in both NAc and CPu, it only tended to increase the expression of the 
GABAA (β-1) receptor and CREB1 in the NAc, but not the CPu. Bifeprunox had no effects 
on PKA signalling in these brain regions. These results suggest that aripiprazole has selective 
effects on up-regulating the GABAA (β-1) receptor and CREB1 in the NAc, probably via 






Introduction     
Gamma-aminobutyric acid (GABA) is one of the major inhibitory neurotransmitters, and has 
been reported to be involved in the pathophysiology of schizophrenia (see review Benes, 
2015). The GABA receptor family consists of three classes of receptors – GABAA, GABAB 
and GABAC; the GABAA receptor is widely distributed in the brain (Hendry et al., 1989). 
Previous studies reported abnormal GABAA receptor density in various brain regions of 
schizophrenia subjects, including the prefrontal cortex (PFC) (Dean et al., 1999, Ishikawa et 
al., 2004), cingulate cortex (Benes et al., 1992), superior temporal gyrus (Deng and Huang, 
2006) and hippocampus (Benes et al., 1997). Antipsychotic drug administration also affects 
GABAA receptors. For example, a 6-month treatment with haloperidol increased the density 
of GABAA receptor binding of [
3H]-muscimol in the caudate putamen (CPu), the core of the 
nucleus accumbens (NAc), while reducing it in the parietal and temporal cortex; both 
haloperidol and clozapine increased the bindings of GABAA receptors in the anterior 
cingulate and infralimbic cortex, respectively (Zink et al., 2004). Skilbeck and colleagues 
(2007) reported that the total population of GABAA receptors was increased by 1-week 
treatment with haloperidol and olanzapine; however, antipsychotic effects diminished in the 
longer treatment groups. Additionally, McLeod et al. (2008) found that administration with 
haloperidol decreased the GABAA binding site in the thalamus but increased binding sites in 
the hypothalamus. It is worth noting that none of the antipsychotics directly binds with 
GABAA receptors, which raises a critical question: which pathway(s) do antipsychotics act 
on to affect the GABAA receptors?  
 
All current antipsychotics act on D2-like receptors (including D2, D3 and D4) to achieve their 
therapeutic effects (Kapur and Mamo, 2003). Typical antipsychotic drugs (e.g. haloperidol) 





schizophrenia (such as delusions, hallucination, disordered speech and behaviours etc.), but 
inducing severe extrapyramidal side-effects (EPS; such as acute dyskinesias and dystonic 
reactions, tardive dyskinesia, and Parkinsonism etc.) (Kapur and Mamo, 2003). Furthermore, 
although binding to multiple receptors (including serotonin 5-HT2A, 5-HT2C, muscarinic 
receptors), the majority of the atypical antipsychotics (e.g. clozapine, olanzapine and 
risperidone) also antagonise D2Rs (Kapur and Mamo, 2003). In recent years, partial agonists 
for D2-like receptors were the focus of the new drug development. Aripiprazole is a 
successful D2 partial agonist that possesses therapeutic effects in schizophrenia, with much 
lower EPS side-effects (Mailman and Murthy, 2010). However, to date, all other partial 
agonists, except aripiprazole, failed to achieve meaningful clinical efficacy for schizophrenia 
or were discontinued due to tolerability and/or safety issues (Benkert et al., 1995, Lahti et al., 
1998). Recently, bifeprunox, a potent partial agonist for the dopamine D2 receptor, exhibited 
therapeutic effects in clinical trials (Casey et al., 2008), but was still disapproved and 
cancelled due to severe side effects (e.g. nausea) and unstable long-term therapeutic effects 
(Casey et al., 2008, Lundbeck, 2009). Therefore, it is necessary to investigate the 
pharmacological mechanism of aripiprazole by comparing it with other D2 partial agonists 
(e.g. bifeprunox).  
 
The G protein-dependent cAMP-PKA pathway is a major downstream signalling pathway of 
D2-like receptors, in which activation of D2-like receptors inhibits the activity of adenylate 
cyclase and synthesis of cAMP via the Gi protein, followed by the inhibition of PKA 
signalling (Beebe, 1994). A post-mortem study found reduced PKA regulatory subunits in 
schizophrenia patients (Tardito et al., 2000), indicating that PKA signalling may be related to 
the pathophysiology of schizophrenia. In vivo studies have suggested that PKA signalling 





olanzapine treatment can increase the expression of PKA catalytic subunits in the CPu in rats 
(Turalba et al., 2004); another study indicated that haloperidol facilitated this signalling 
(Kaneko et al., 1992); furthermore, the activity of the cAMP-PKA pathway and expression of 
PKA regulatory subunits in the striatum were elevated after 3-week treatment with 
haloperidol, whereas clozapine displayed opposite effects in various brain areas (Dwivedi et 
al., 2002).  
 
PKA kinase regulates several downstream substrates that are involved in the pathophysiology 
of schizophrenia. The GABAA receptor can be regulated by D2-like receptor-mediated PKA 
signalling (Connelly et al., 2013). In addition, cAMP-responsive element-binding protein 
(CREB) is another PKA downstream substrate (Shaywitz and Greenberg, 1999). Novel 
variants in the CREB gene have been identified in schizophrenic patients who have 
experienced the positive symptoms of schizophrenia (Kawanishi et al., 1999). Previous 
studies revealed that haloperidol increased phosphorylation levels of CREB in both in vivo 
and in vitro studies (Konradi and Heckers, 1995, Pozzi et al., 2003, Yang et al., 2004). Both 
amisulpride and clozapine can also induce the phosphorylation of CREB in vitro (Jeon et al., 
2015, Park et al., 2011). Therefore, we proposed that antipsychotic drugs may modulate 
GABAA receptors and CREB1 activity through the PKA signalling pathway. The present 
study investigated the effects of antipsychotics on the PKA downstream GABAA receptors, 
and CREB1.  
 
Methods 
Animals and drug administration 
Male Sprague-Dawley rats (aged 8 weeks) were obtained from the Animal Resource Centre 





environmentally controlled conditions (temperature 22°C, light cycle from 07:00 AM to 
07:00 PM), with ad libitum access to water and standard laboratory chow diet. All 
experimental procedures were approved by the Animal Ethics Committee (Application #: 
AE11/02), University of Wollongong, and complied with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes (2004). All animals were euthanised 
using carbon dioxide. All efforts were made to minimise animal distress and prevent 
suffering. 
 
Before the drug administration commenced, the rats were fed with cookie dough (containing 
sucrose 30.9%, corn starch 30.9%, casein 15.5%, minerals 8.4%, fibre 6.4%, gelatine 6.3% 
and vitamins 1.6%) without drugs for 1 week to train them to self-administrate the drug. Then 
rats were randomly assigned into one of the following drug groups (n = 6 / group) and orally 
treated with cookie dough mixed with the drug powder: aripiprazole (0.75 mg/kg, t.i.d. (ter in 
die); Otsuka, Japan), bifeprunox (0.8 mg/kg, t.i.d.; Otava, Ukraine), haloperidol (0.1 mg/kg, 
t.i.d.; Sigma, Australia), or vehicle for 1 week. Water was added to achieve a dry-dough 
consistency immediately prior to administration. Rats were offered cookies with drugs by a 
metal spoon three times a day (at 06:00 AM, 02:00 PM and 10:00 PM) and observed to 
ensure complete consumption of each pellet. These dosages were equivalent to the 
recommended dosage in the clinic, and they were translated based on body surface area 
according to the FDA guidelines for clinical trials (FDA, 2005, Reagan-Shaw et al., 2008). 
This drug administration method has been well established in our laboratory (De Santis et al., 
2014, Deng et al., 2015). A 0.75 mg/kg aripiprazole dosage in rats is equivalent to ~7.5 mg in 
humans (60 kg body weight), while 0.8 mg/kg bifeprunox and 0.1 mg/kg haloperidol is 
equivalent to ~8 mg and ~1 mg respectively, all of which are within the used/recommended 





that aripiprazole and bifeprunox, at these dosages, had over 90% D2 receptor occupancy in rat 
brains (Wadenberg, 2007), while haloperidol reached approximately 70% D2R occupancy 
(Kapur et al., 2003, Naiker et al., 2006, Natesan et al., 2006). Furthermore, the dosages used 
in this study have been shown to be physiologically and behaviourally effective in rodents 
(Assie et al., 2006, De Santis et al., 2014, Han et al., 2009, Kesby et al., 2006, Wadenberg, 
2007), whilst not causing EPS side-effects (Natesan et al., 2006, Wadenberg, 2007). After 1-
week administration, all rats were sacrificed between 10:00 AM and 12:00 PM to minimise 
possible circadian-induced variation of protein expression. Brains were immediately removed, 
frozen in liquid nitrogen and stored at -80°C until required. 
 
Microdissection  
Following a standard procedure used in our lab, discrete brain regions were collected using 
brain microdissection puncture, which has been performed successfully (Pan et al., 2015). 
Based on the brain atlas (Paxinos and Watson, 2005), three sections through the forebrain 
(Bregma 3.30 to 4.20 mm) were dissected for the PFC; three sections through the striatum 
(Bregma 1.00 to 2.20 mm) were dissected for the NAc and CPu, respectively. The three brain 
regions were chosen because they are key brain areas involved in the effects of antipsychotics. 
Tissue obtained was stored at -80°C until use. 
 
Western Blots 
The Western Blots procedures were described previously (Lian et al., 2014, Pan et al., 2015). 
Tissue was homogenised with NP-40 cell lysis buffer (Invitrogen, Camarillo, CA, USA) 
mixed with Protease Inhibitor Cocktail (Sigma-Aldrich, St Louis, MO, USA), β-
Glycerophosphate (Invitrogen) and phenylmethylsulfonylfluoride (Sigma-Aldrich). The 





concentrations of the supernatants were determined spectrophotometrically using the DC 
Protein Assay (Bio-Rad, #500-0111). Samples containing 10 µg of protein were resolved by 
10% SDS-PAGE gels, and then transferred electrophoretically to a polyvinylidene difluoride 
membrane using Bio-Rad Midi Format 1-D Electrophoresis Systems. The membranes were 
blocked by 5% skim milk and incubated in primary antibodies. Amersham Hyperfilm ECL 
(GE Healthcare, #28-9068-36) was used to visualise the immunoreactive bands. The 
immunoreactive signals were quantified using Bio-Rad Quantity One software. The data were 
normalised to the corresponding actin levels. Experiments of Western Blots were performed 
in duplicate to ensure consistency. 
    
Two catalytic (Cα and Cβ) isoform of PKA subunits have been previously identified (Cadd 
and McKnight, 1989). PKA-Cα expression was measured due to its highest expression in 
brain tissues (Soberg et al., 2013, Uhler et al., 1986). Therefore, two antibodies for PKA 
subunits were chosen in the present study: anti-PKA-Cα (1:1000; Santa Cruz, #SC-903) and 
anti-phosphor-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). Subunits of GABAA 
receptors and CREB1 were examined using: anti-GABAA β-1 (1:1000; Abcam, #ab154822), 
anti-GABAA β-2 (1:1000; Abcam, #ab156000), anti-GABAA β-3 (1:1000; Abcam, #ab98968) 
and anti-CREB1 (1:1000; Abcam, #ab32515). Mouse anti-actin primary polyclonal antibody 
(1:10000; Millipore, #MAB1501) were used to determine the actin levels. The secondary 
antibodies used in this study were HRP-linked anti-rabbit IgG antibody (1:3000; Cell 
Signalling, #7074) and HRP-linked anti-mouse IgG antibody (1:3000; Cell Signalling, 
#7076).  
 





Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure the 
mRNA expression levels of Gabrb1, Gabrb2, Gabrb3 and Creb1 in the brain regions where 
the PKA signalling was significantly affected by antipsychotic drug administration. The qRT-
PCR procedures were described previously (Liu et al., 2015). Briefly, PureLink® RNA Mini 
Kit (Invitrogen Life Technologies, Carlsbad, CA, USA) was used to extract RNA. First-
strand cDNA was synthesised from RNA with Superscript® VILOTM cDNA Synthesis Kit 
(Life Technologies, NSW, Australia) by incubation at 42 °C for 60 min. Then, each sample 
cDNA was performed qRT-PCR in duplicate using TaqMan® Gene Expression Assays 
(Applied Biosystems, Foster City, USA) on LightCycler® 480 (Roche, Penzberg, Germany). 
The assay (Life Technologies, NSW, Australia) identifications of the target genes were 
Gabrb1 (Rn00564146_m1), Gabrb2 (Rn00564149_m1), Gabrb3 (Rn00567029_m1) and 
Creb1 (Rn00578828_g1). All gene expression levels were normalized relative to two 
endogenous control genes glyceraldehyde-3-phosphatedehydrogenase (GAPDH) 
(Rn01775763_g1) and β-actin (Rn00667869_m1).  The 2-ΔΔCT method was used to 
calculate the results. 
 
Statistics  
All data were analysed using the SPSS Statistics v22.0 program. The data of both Western 
Blots and qRT-PCR experiments were normalised by taking the average value of the control 
group as 100% and expressed as mean ± S.E.M. The individual control value was also 
normalised to the average of overall control experiments for statistical analysis. The 
phosphorylated protein p-PKA was normalised by the levels of total PKA-Cα. Normality test 
was performed to test data distribution. One-way analysis of variance (ANOVA) was 
performed if the data was normally distributed, followed by Post-hoc Dunnett t test to 





analyse the relationships among the measurements. Statistical significance was accepted 
when p < 0.05. 
 
Results  
Antipsychotic drug effects on PKA signalling 
PFC. The expression of PKA-Cα subunits in the PFC was significantly affected by 1-week 
drug administration (F3, 20 = 3.723, p < 0.05). In comparison with the control group, 
administration with aripiprazole induced a significant elevation in the protein levels of PKA-
Cα (123.6 ± 3.7%, p < 0.05) (Fig. 1A & 1D). However, no drug significantly affected the 
levels of p-PKA and the ratio of p-PKA/PKA (Fig. 1A). 
 
NAc. It was shown that antipsychotic drug administration had a significant effect on the 
levels of p-PKA (F3, 20 = 13.123, p < 0.01) and the ratio of p-PKA/PKA (F3, 20 = 3.216, p < 
0.05) in the NAc. It was further revealed that administration with both aripiprazole and 
haloperidol was able to significantly elevate the levels of p-PKA (aripiprazole: 134.3 ± 7.0%, 
p < 0.01; haloperidol: 140.6 ± 6.0%, p < 0.01) in the NAc (Fig. 1B & 1D). The ratio of p-
PKA/PKA was also significantly increased by administration with aripiprazole (118.0 ± 7.5%, 
p < 0.05) and haloperidol (118.6 ± 3.8%, p < 0.05) (Fig. 1B).  
 
CPu. In the CPu, drug administration significantly altered the protein levels of PKA-Cα (F3, 
20 = 24.183, p < 0.01) and p-PKA (F3, 20 = 16.281, p < 0.01) and the ratio of p-PKA/PKA (F3, 
20 = 20.043, p < 0.01). Post-hoc tests showed all three chemicals were able to significantly 
elevate the expression of PKA-Cα in the CPu (aripiprazole: 159.3 ± 3.5%, p < 0.01; 
bifeprunox: 126.7 ± 7.1%, p < 0.01; haloperidol: 125.0 ± 5.4%, p < 0.01). However, only 





The ratio of p-PKA/PKA was significantly reduced by aripiprazole administration (61.0 ± 
1.6%, p < 0.01), but increased by haloperidol administration (148.5 ± 12.4%, p < 0.01) (Fig. 
1C).  
 
Antipsychotic drug effects on mRNA and protein expression of GABAA subunits and 
CREB1 
Since significant antipsychotic drug effects on the activation of PKA signalling were 
observed in the NAc and CPu, GABAA receptors and CREB1 were examined in these two 
brain regions. The results showed that the mRNA expression levels of Gabrb1 (F3, 20 = 7.898, 
p < 0.01) were significantly altered by antipsychotic drug administration in the NAc. 
Furthermore, both aripiprazole and haloperidol administration up-regulated the mRNA levels 
of Gabrb1 (aripiprazole: 125.7 ± 4.7%, p < 0.05; haloperidol: 135.2 ± 4.2%, p < 0.01), 
whereas the mRNA levels of Gabrb2 and Gabrb3 were not significantly altered by any drug 
administration (all p > 0.05) (Fig. 2A). In Western Blots, it was revealed that drug 
administration significantly changed the levels of GABAA β-1 (F3, 20 = 7.627, p < 0.01) in the 
NAc. Post-hoc tests demonstrated that administration with aripiprazole was able to elevate 
significantly the levels of GABAA β-1 (164.3 ± 13.1%, p < 0.01) (Fig. 3A & 3C) in the NAc; 
in addition, haloperidol showed trends to increase the expression of GABAA β-1 (126.1 ± 
7.3%, p < 0.1) in the NAc. It is worth noting that the protein levels of GABAA β-1 was also 
positively correlated with the levels of p-PKA (r = 0.691, p < 0.05) (Fig. 4A) and the ratio of 
p-PKA/PKA (r = 0.583, p < 0.05) in the NAc (Fig. 4B). On the other hand, in the CPu, 
neither the mRNA levels (Fig. 2B) nor the protein expression of the subunits of GABAA 






It was also observed that the mRNA expression levels of Creb1 (F3, 20 = 2.952, p < 0.05) were 
significantly altered by antipsychotic drug administration in the NAc. Post-hoc tests indicated 
that both aripiprazole and haloperidol administration significantly elevated the mRNA levels 
of Creb1 (aripiprazole: 124.1 ± 5.3%, p < 0.05; haloperidol: 125.7 ± 7.7%, p < 0.01) in the 
NAc (Fig. 2A). Western Blots indicated that drug administration significantly changed the 
levels of CREB1 (F3, 20 = 3.656, p < 0.05) in the NAc. Post-hoc tests showed that 
administration with aripiprazole was able to significantly promote the expression of CREB1 
(127.4 ± 5.9%, p < 0.05) (Fig. 3A & 3C) in the NAc; additionally, haloperidol also elevated 
the protein levels of CREB1, but did not reach significance (119.1 ± 6.7%, p < 0.1). 
Moreover, the protein expression of CREB1 was positively correlated with the levels of p-
PKA (r = 0.371, p < 0.05) (Fig. 4C), as well as the ratio of p-PKA/PKA (r = 0.750, p < 0.01) 
in the NAc (Fig. 4D). On the other hand, in the CPu, no drug administration significantly 
changed either the mRNA levels of Creb1 (all p > 0.1) (Fig. 2B) or its protein expression (Fig. 
3B & 3D). 
 
Discussion 
The present study measured the in vivo effects of antipsychotics on PKA signalling in the 
PFC, NAc and CPu. We observed significant effects on PKA signalling induced by 
aripiprazole and haloperidol in the NAc and CPu. Aripiprazole and haloperidol, but not 
bifeprunox, activated PKA phosphorylation in the NAc. However, different effects were 
observed in the CPu – aripiprazole, unlike haloperidol, inhibited PKA activity in the CPu. 
Further analysis showed that mRNA expression and protein levels of GABAA receptors 
(containing β-1 subunit) and CERB1 were up-regulated by both aripiprazole and haloperidol 
administration, and were also significantly correlated with p-PKA levels and/or the ratios of 





the expression of GABAA and CREB1 through PKA signalling in the NAc. In the CPu, on 
the other hand, unexpectedly, GABAA receptors and CREB1 were not significantly altered by 
aripiprazole and haloperidol, although they changed the ratios of p-PKA/PKA. 
 
The present study demonstrated that haloperidol enhanced PKA activity in the NAc and CPu 
by increasing the levels of p-PKA and/or the ratio of p-PKA/PKA. Previously, a study 
showed the protein levels of PKA-Cα were elevated in the CPu by acute administration with 
haloperidol, but not in the PFC and NAc (Turalba et al., 2004). A long-term study revealed 
that the activity of the cAMP-PKA pathway in the striatum was significantly increased after 
administration with haloperidol for 3 weeks (Dwivedi et al., 2002). Our results are consistent 
with those of previous studies, suggesting that haloperidol is able to antagonise D2-like 
receptors to increase PKA signalling. Furthermore, our study is the first study to examine the 
effects of aripiprazole; we found increased PKA phosphorylation levels and an increased 
ratio of p-PKA/PKA in the NAc, which is similar to the effects of haloperidol in this brain 
region, suggesting its antagonistic effects on D2-like receptors. It is interesting that 
aripiprazole reduced the ratio of p-PKA/PKA in the CPu in the present study, whereas 
haloperidol increased it. This reduction may indicate that aripiprazole exerts agonistic effects 
on D2-like receptors together with endogenous dopamine in this brain region. Moreover, 
aripiprazole is a functionally selective ligand for the dopamine D2 receptor (Han et al., 2009, 
Mailman and Murthy, 2010). These opposite effects of aripiprazole on PKA signalling in the 
NAc and CPu might be (at least partly) attributed to its functional selectivity for the D2 
receptor. This may also explain why aripiprazole has fewer EPS side-effects than haloperidol, 
since haloperidol can increase PKA signalling in both the NAc and CPu. Lastly, bifeprunox 





possesses a high level of intrinsic activity (Tadori et al., 2007), exhibiting overall agonistic 
effects with endogenous dopamine.  
 
We further observed that haloperidol enhanced PKA activity in the CPu. However, 
aripiprazole reduced it by decreasing the ratio of p-PKA/PKA, probably due to its functional 
selectivity for the D2 receptor, as discussed earlier. It was also revealed that aripiprazole may 
act as a potent partial agonist, weak agonist, or antagonist depending upon the cellular 
environments of the targeted D2 receptors (Burris et al., 2002, Kikuchi et al., 1995, Lawler et 
al., 1999, Mailman and Murthy, 2010, Shapiro et al., 2003, Urban et al., 2007). It should be 
noted that the NAc and CPu are heterogeneous structures with different connections with 
various brain regions (reviewed by Yager et al., 2015). For example, the NAc receives 
dopaminergic inputs from the ventral tegmental area (VTA) and links with limbic areas and 
the PFC, while the CPu receives dopaminergic inputs from the substantia nigra pars (SN) and 
links with neocortical areas, particularly the motor areas (Yager et al., 2015). Blockade of 
dopamine D2 receptor activity in the mesolimbic (VTA–NAc) pathway is the common 
mechanism of antipsychotic actions, particularly in the control of positive symptoms of 
schizophrenia (Ginovart and Kapur, 2012); in addition, EPS side-effects induced by 
antipsychotics are related to the blockade of D2 receptors in the nigrostriatal (SN–CPu) 
pathway (Tauscher et al., 2002). Since the cellular environments are distinct between the 
NAc and CPu, this theory of functional selectivity may be applied to the present study to 
explain the regional differences of aripiprazole on PKA signalling. However, the previous 
evidence was primarily based on in vitro studies (Burris et al., 2002, Kikuchi et al., 1995, 
Lawler et al., 1999, Mailman and Murthy, 2010, Shapiro et al., 2003, Tadori et al., 2011, 
Tadori et al., 2007, Tadori et al., 2005, Urban et al., 2007), and the in vivo effects of 





various mental disorders, the extra- and intra-cellular environments should be different in the 
patients’ brains from those of the normal subjects. Therefore, it could be reasoned that 
psychoactive drugs may affect the PKA signalling differently in patients or rodent models for 
schizophrenia (such as the amphetamine and phencyclidine rat models, neuregulin-1 and 
ErbB4 knock-out models for schizophrenia, etc.).    
 
Hypofunction of dopamine signalling in the PFC has been found in schizophrenia subjects, 
and it is believed that this hypofunction of dopamine signalling is connected with the 
negative symptoms of schizophrenia (Howes and Kapur, 2009). Therefore, it can be assumed 
that aripiprazole can exert agonistic effects on D2-like receptors under hypo-dopaminergic 
conditions. Unexpectedly, we did not observe this agonistic effect in the PFC in the current 
study. This study used healthy animals with normal dopamine signalling; in this situation, the 
intrinsic activity of aripiprazole may not be potent enough to increase dopamine signalling 
when it acts together with endogenous dopamine, so that we could not observe the agonistic 
effect of aripiprazole while it happens under hypo-dopaminergic condition.  
 
Previous evidence suggests that dysfunction in the GABA system is implicated in the 
pathophysiology of schizophrenia (Lewis et al., 2004); and the GABAA receptor can be 
regulated by D2-like receptor-mediated PKA signalling (Connelly et al., 2013, Poisbeau et al., 
1999). In this study, we found that both aripiprazole and haloperidol administration, but not 
bifeprunox, were able to significantly increase mRNA expression of Gabrb1 in the NAc after 
1-week administration, whereas in the CPu no alterations in the GABAA receptor were 
induced by antipsychotic drug administration. In addition, both aripiprazole and haloperidol 
elevated the protein expression of GABAA (containing β-1) receptor (although the increasing 





haloperidol administration increased the binding density of GABAA receptors in the NAc 
(Zink et al., 2004), which is consistent with the finding of the present study. However, the 
effects of antipsychotics on the GABAA receptor are quite brain region-dependent. Zink et al. 
(2004) also revealed that haloperidol reduced GABAA receptor binding in the temporal and 
parietal cortex, and both haloperidol and clozapine reduced it in the anterior cingulate and 
infralimbic cortex. Additionally, 1-week administration with both haloperidol and olanzapine 
increased the binding of GABAA receptors in the PFC (Skilbeck et al., 2007). Tanahashi et al. 
(2012) and Peselmann et al. (2013) also suggested that aripiprazole affected GABA 
signalling in a brain region-dependent manner.  
 
In this study, both aripiprazole and haloperidol have the ability to facilitate PKA activity and 
increase the levels of the GABAA receptor; we also revealed that the mRNA levels of 
GABAA receptors are positively correlated with both the levels of p-PKA and the ratio of p-
PKA/PKA. It is therefore suggested that the regulation of GABAA receptors by 
antipsychotics in the NAc might occur through regulating PKA signalling via D2-like 
receptors. In addition, since dysfunction of the NAc is involved in the positive symptoms of 
schizophrenia (Mikell et al., 2009) and the positive symptoms could be controlled by 
blocking D2 receptors in NAc, our finding further suggests that PKA-GABAA signalling 
transmission is very likely to be involved in the therapeutic effects of antipsychotics (possibly 
in the positive symptoms of schizophrenia) (Fig. 5). On the other hand, antipsychotic 
administration did not exert any effects on the GABAA receptor in the CPu, whereas 
significant effects were revealed in the previous study after chronic haloperidol treatment 
(Zink et al., 2004). This discrepancy may be due to the treatment period. It seems likely that 
antipsychotic administration needs longer to exert a delayed effect on the GABAA receptor in 






It should be noted that GABAA signalling was increased in various brain regions in 
schizophrenia subjects in post-mortem studies (Benes et al., 1992, Benes et al., 1997, Dean et 
al., 1999, Deng and Huang, 2006, Hanada et al., 1987, Ishikawa et al., 2004, Woo et al., 
2004) (although conflicting data existed (Pandey et al., 1997, Squires et al., 1993)). However, 
our study exhibited increasing effects of antipsychotics on GABAA signalling in the NAc, 
which was also reported by Zink et al., (2004). These findings conflict with the situation 
observed in schizophrenia patients. Since most schizophrenia subjects have been exposed to 
chronic antipsychotic treatment, the increased GABAA signalling observed in post-mortem 
tissues might be at least partially a secondary effect of chronic antipsychotic treatment. 
Additionally, there is no post-mortem data that directly describes the changes in GABAA 
signalling in the NAc of schizophrenia patients, and further related studies are required to 
address this issue. 
 
Novel variants in the CREB gene have been identified in schizophrenic subjects (Kawanishi 
et al., 1999, Shaywitz and Greenberg, 1999). CREB can be phosphorylated by PKA and 
affected by antipsychotic administration (Dash et al., 1991). Previous studies reported that 
haloperidol was able to increase phosphorylation levels of CREB both in vivo and in vitro 
(Konradi and Heckers, 1995, Pozzi et al., 2003, Yang et al., 2004). In addition, atypical 
antipsychotics amisulpride and clozapine can also induce phosphorylation of CREB in vitro 
(Jeon et al., 2015, Park et al., 2011). The above antipsychotics are all D2R antagonists, which 
may indicate that dis-inhibition of cAMP and activation of PKA via antagonising D2-like 
receptors leads to increased activity of CREB. In the present study, administration with 
haloperidol significantly increased mRNA expression of CREB1, as well as its protein 





findings (Konradi and Heckers, 1995, Pozzi et al., 2003, Yang et al., 2004). Our study is the 
first study to examine the in vivo effects of D2 partial agonists (e.g. aripiprazole) on CREB so 
far. We observed that aripiprazole had positive effects on elevating the protein expression and 
mRNA levels of CREB1 in the NAc, whereas bifeprunox had no such effects. Since patients 
with novel variants in the CREB gene experienced the positive symptoms of schizophrenia 
(Kawanishi et al., 1999), up-regulation of CREB1 in the NAc is very likely to be associated 
with the therapeutic effects of antipsychotics on the positive symptoms of schizophrenia. Fig. 
5 depicts a proposed mechanism indicating that antipsychotics activate PKA signalling via 
antagonising D2-like receptors, and might link to the increase in the expression of CREB1 to 
exert therapeutic effects on the positive symptoms of schizophrenia. 
 
It is worth noting that CREB activity can also be affected by the mitogen-activated protein 
kinase (MAPK)/extracellular signal-regulated kinases (ERK) signalling cascade, and this 
regulation plays a role in schizophrenia (Kyosseva et al., 1999). Previously, both ERK and 
CREB activity were reported to be up-regulated by both haloperidol and risperidone (Yang et 
al., 2004). Therefore, MAPK/ERK signalling cascade via D2-associated Gβγ protein is another 
possible (probably indirect) signalling pathway by which aripiprazole and haloperidol 
regulate CREB1 to achieve their therapeutic effects on the positive symptoms of 
schizophrenia. Therefore, the role of MAPK/ERK-mediated CREB1 activity in the 
antipsychotic treatment of schizophrenia is worthy exploring in the future. 
 
In summary, the present study demonstrated that aripiprazole was able to increase the 
expression of GABAA (containing β-1 subunit) receptor and CREB1 in the NAc, which were 
significantly correlated with the enhanced PKA signalling. However, further studies are 





mediated PKA pathway by (1) using specific D2R antagonists, such as L-741,626 in 
combination with the antipsychotic drugs, (2) evaluating transcription factor phosphorylation, 
and (3) inhibiting PKA signalling. This study also suggested that aripiprazole may have 
functionally selective effects on the dopamine D2 receptor to differentially regulate PKA 
signalling in the NAc and CPu. Further studies are required to explore what roles the up-
regulation of GABAA receptors and CREB1 induced by antipsychotics plays in the treatment 
of schizophrenia. It is worthy noting that the present and previous studies mentioned above 
examined the effects of antipsychotic drugs on the PKA-related signalling pathways only in 
healthy animals. It is, therefore, necessary to investigate whether these drugs have similar 
effects in the animal models for schizophrenia and other mental disorders in future studies. 
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 The effects of control (CON), aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL) 
on PKA signalling were measured in the prefrontal cortex (A), nucleus accumbens (B) and 
caudate putamen (C). The representative bands of Western blot are shown in (D). PKA-Cα 
was quantified at 42kDa; p-PKA was quantified at 42kDa. The data were normalised by 
taking the average value of the control group as 100% and expressed as mean ± S.E.M. (* p ≤ 
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The effects of control (CON), aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL) 
on the PKA downstream Gabrb1, Gabrb2, Gabrb3 and Creb1 were measured in the nucleus 

























































The effects of control (CON), aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL) 
on the GABAA β-1, β-2 and β-3 subunits, as well as CREB1, were measured in the nucleus 
accumbens (NAc) (A) and caudate putamen (CPu) (B). The representative bands of Western 
blot of the NAc and CPu are shown in (C) and (D), respectively. GABAA β-1, β-2 and β-3 
subunits were quantified at 54, 59, 55 kDa, respectively. CREB1 was quantified at 40k Da. (* 



















CON   ARI BIF  HAL
β-actin










Figure 4. Correlations between mRNA expression of Gabrb1 and Creb1 with the 
activation of PKA signalling in the NAc.  
 
 
The mRNA expression of Gabrb1 is positively correlated with the levels of p-PKA (A) and 
the ratio of p-PKA/PKA (B) in the NAc. The mRNA expression of Creb1 is positively 




r = 0.691, p < 0.05 r = 0.583, p < 0.05





Figure 5. Possible mechanisms of increased expression of GABAA and CREB1 by 





D2-like receptor activation can be reduced by D2 receptor antagonists (e.g. haloperidol) and 
D2 receptor partial agonists with low intrinsic activity (e.g. aripiprazole) (A), resulting in 
decreased inhibition (indicated by “ X  ”) of adenylyl cyclase (AC), followed by an increased 
cAMP level and PKA activation (B). The activation of PKA signalling may lead to increased 
expression of GABAA (β-1) receptors (C) and enhanced CREB1-dependent gene expression 
(D), which might be involved in the therapeutic actions of antipsychotics. 
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